Specific vash compounds (svc) inhibitors for heart diseases

A method for the prevention and/or the treatment of heart failure, cardiomyopathies, myocardial infarction induced cardiac dysfunction, and/or for improving heart function in a subject in need thereof, comprising the administration to a subject in need thereof of an effective dose of a compound of formula (I):

• or a pharmaceutically acceptable salt and/or solvate thereof,
• in which
• X is
• or —NH—CH2—
• R1 is
• or NR1aR1b with R1a is H and R1b is C1-C6 alkyl non substituted or substituted with C(O)—O—C1-C6 alkyl or C(O)—NH—C1-C6 alkyl,
• R is O—R2 with R2 is a C1-C6 aliphatic chain, said aliphatic chain being substituted or not substituted, or C1-C6 alkyl-aryl,
• R3 is OH or O—C1-C6 aliphatic chain,
• Y is —(CH2)m— with m=2 or
• R5 is C(O)OH or O—C1-C6 alkyl, and
• R6 is NH—CH(R7)—(CH2)n—R8 with R7 is H and R8 is aryl and n is 1, 2 or 3, or O—C1-C6 aliphatic chain.